Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
暂无分享,去创建一个
F. Rey | H. Mouquet | O. Schwartz | M. Prot | S. Fafi-Kremer | D. Planas | H. Péré | L. Bélec | I. Staropoli | T. Bruel | F. Guivel-Benhassine | D. Veyer | E. Simon-Lorière | L. Hocqueloux | N. Kassis-Chikhani | T. Prazuck | C. Planchais | A. Sève | F. Porrot | F. Gallais | N. Kassis-Chikhani | A. Baidaliuk | A. Velay | P. Gantner | Nicolas Robillard | J. Le Guen | M. M. Rajah | L. Courtellemont | J. Puech | Dhiaeddine Edriss
[1] P. Dormitzer,et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants , 2021, Nature.
[2] C. Swanton,et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination , 2021, The Lancet.
[3] N. Andrews,et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant , 2021, medRxiv.
[4] William L. Hamilton,et al. SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough , 2021 .
[5] H. Jäck,et al. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination , 2021, bioRxiv.
[6] S. Singh,et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India , 2021, bioRxiv.
[7] S. Panda,et al. Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees , 2021, bioRxiv.
[8] P. Taylor,et al. Neutralizing monoclonal antibodies for treatment of COVID-19 , 2021, Nature Reviews Immunology.
[9] Adam S. Dingens,et al. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016 , 2021, Cell Reports Medicine.
[10] H. Mouquet,et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. , 2021, Nature medicine.
[11] M. Beltramello,et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 , 2021, Cell.
[12] V. Simon,et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine , 2021, The New England journal of medicine.
[13] D. Ho,et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.
[14] Vineet D. Menachery,et al. The variant gambit: COVID-19’s next move , 2021, Cell Host & Microbe.
[15] J. Bloom,et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 , 2021, Science.
[16] A. Fontanet,et al. Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection , 2021 .
[17] M. Nussenzweig,et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies , 2020, Nature.
[18] Philip L. Tzou,et al. Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds , 2020, Viruses.
[19] J. Sodroski,et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike , 2020, Nature.
[20] S. Rawson,et al. Distinct conformational states of SARS-CoV-2 spike protein , 2020, Science.
[21] Edward C. Holmes,et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology , 2020, Nature Microbiology.
[22] H. Mouquet,et al. Syncytia formation by SARS‐CoV‐2‐infected cells , 2020, bioRxiv.
[23] A. Fontanet,et al. Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France , 2020, EBioMedicine.
[24] Trevor Bedford,et al. Nextstrain: real-time tracking of pathogen evolution , 2017, bioRxiv.
[25] H. Mouquet,et al. Efficient generation of human IgA monoclonal antibodies. , 2015, Journal of immunological methods.